Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 1,736 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Administration first Clear all

Conditions: SARS CoV 2 Infection
Interventions: EDP-235, Placebo; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Nocturia
Interventions: Placebo, Paxerol - Dose Level 1, Paxerol - Dose Level 2, Paxerol - Dose Level 3; Other · Drug
Lead sponsor: Wellesley Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 4
States / cities: Brooklyn, New York • Harrison, New York • New York, New York

Conditions: Acute Kidney Injury
Interventions: ANG-3777, Placebo; Drug
Lead sponsor: Angion Biomedica Corp; Industry
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 23
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 18 more

Conditions: Ischemia-Reperfusion Injury, Lung Transplantation
Interventions: Repertaxin, Placebo; Drug · Other
Lead sponsor: Dompé Farmaceutici S.p.A; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 5
States / cities: Los Angeles, California • Denver, Colorado • St Louis, Missouri + 2 more

Conditions: HIV Infections, Peripheral Nervous System Disease
Interventions: Amitriptyline hydrochloride, Amitriptyline hydrochloride placebo, Point acupuncture; Drug · Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 1997
U.S. locations: 11
States / cities: San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 7 more

Conditions: Separation Anxiety Disorder, Generalized Anxiety Disorder, Social Phobia
Interventions: Acoustic Neuromodulation (ANM); Other
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 7 Years to 17 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Impaired Glucose Tolerance
Interventions: Resveratrol, resveratrol /HMB, Placebo treatment; Dietary Supplement · Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: COVID-19, SARS-CoV-2 Infection, Coronavirus Infection
Interventions: TXA127, TRV027, Placebo, Fostamatinib; Drug
Lead sponsor: Sean Collins; Other
Eligibility: 18 Years and older
Enrollment: 1,060 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 51
States / cities: Birmingham, Alabama • Chandler, Arizona • Los Angeles, California + 40 more

Conditions: Nonsquamous Nonsmall Cell Neoplasm of Lung
Interventions: Pemetrexed, Carboplatin, demcizumab; Drug
Lead sponsor: OncoMed Pharmaceuticals, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 18
States / cities: Rancho Mirage, California • San Francisco, California • New Haven, Connecticut + 14 more

Conditions: Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia
Interventions: Mitapivat, Mitapivat-matching placebo; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 9
States / cities: Phoenix, Arizona • Palo Alto, California • Atlanta, Georgia + 6 more

Conditions: Post-bariatric Hypoglycemia
Interventions: glucagon, Closed loop glucagon pump; Drug · Device
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions: Femara, Placebo; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lung Cancer
Interventions: Pembrolizumab, Epacadostat, Platinum-based chemotherapy, Placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 21
States / cities: Daphne, Alabama • Goodyear, Arizona • Tucson, Arizona + 18 more

Conditions: Optic Neuritis
Interventions: Atacicept, Placebo matched to atacicept; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 8
States / cities: Birmingham, Alabama • Aurora, Colorado • Fairfield, Connecticut + 5 more

Conditions: Distributive Shock
Interventions: Angiotensin II, Placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Endometriosis, CBD, Pelvic Pain
Interventions: Cannabidiol (CBD) Extract, Norethindrone Acetate, Placebo; Drug · Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Corneal Neovascularization
Interventions: Placebo, IL-1Ra; Drug
Lead sponsor: Reza Dana, MD; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Early Alzheimer's Disease
Interventions: Experimental: ALZ-801, Placebo Comparator: Placebo; Drug
Lead sponsor: Alzheon Inc.; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 55
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 50 more

Conditions: Dup15q Syndrome
Interventions: Basmisanil, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 2 Years to 14 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Los Angeles, California • Chicago, Illinois

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: HEC 68498, Placebo; Drug
Lead sponsor: Sunshine Lake Pharma Co., Ltd.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Anorexia Nervosa, Osteopenia, Osteoporosis, Eating Disorders
Interventions: Recombinant Human Growth Hormone, Placebo for Recombinant Human Growth Hormone; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 14 Years to 45 Years · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Oligospermia, Teratospermia, Asthenozoospermia, Male Infertility
Interventions: Ramipril, Placebo; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Ileus
Interventions: MOA-728, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 374 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 75
States / cities: Benton, Arkansas • Colton, California • Laguna Hills, California + 62 more

Conditions: Nicotine Dependence, Major Depressive Disorder
Interventions: Varenicline, BASC, Standard treatment; Drug · Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 2
States / cities: Chicago, Illinois • Philadelphia, Pennsylvania

Search by objective public record fields.

A Study of EDP-235 in Healthy Subjects

Paxerol™ for Treatment of Nocturia - A Phase II Placebo-Controlled Trial

Study to Prevent Acute Kidney Injury After Cardiac Surgery Involving Cardiopulmonary Bypass

Repertaxin in Prevention of Primary Graft Dysfunction After Lung Transplantation

The Efficacy of a Standardized Acupuncture Regimen and Amitriptyline Compared With Placebo as a Treatment for Pain Caused by Peripheral Neuropathy in HIV-Infected Patients

Acoustic Neuromodulation (ANM) for Youth With Anxiety Disorders

Resveratrol-Leucine Metabolite Synergy in Pre-diabetes

Novel Experimental COVID-19 Therapies Affecting Host Response

A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer

A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period

Closed-Loop Glucagon Pump for Treatment of Post-Bariatric Hypoglycemia

Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)

Atacicept in Subjects With Optic Neuritis

Angiotensin II for Distributive Shock

Cannabidiol and Management of Endometriosis Pain

Topical IL-1-Ra for Treatment of Corneal Neovascularization

An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects

A Study to Evaluate the Safety and Efficacy of Basmisanil Treatment in Children Aged 2-14 Years With Dup15q Syndrome

The Safety, Tolerability and Pharmacokinetic Study of HEC68498 in Healthy Male and Female Subjects

Effect of Growth Hormone on Bone Metabolism in Anorexia Nervosa

Ramipril for the Treatment of Oligospermia

A Study Evaluating Intravenous (IV) MOA-728 for the Treatment of Postoperative Ileus (POI) in Participants After Ventral Hernia Repair

Behavioral Activation and Varenicline for Smoking Cessation in Depressed Smokers